Comparison of the safety and efficacy of fixed-dose combination of arterolane maleate and piperaquine phosphate with chloroquine in acute, uncomplicated Plasmodium vivax malaria: A phase III, multicentric, open-label study

Malaria Journal

Volumn 15, Issue 1, 2016, Pages

  Valecha, Neena ^a   Savargaonkar, Deepali ^a   Srivastava, Bina ^a   Rao, B H Krishnamoorthy ^b   Tripathi, Santanu K ^c   Gogtay, Nithya ^d   Kochar, Sanjay Kumar ^e   Kumar, Nalli Babu Vijaya ^f   Rajadhyaksha, Girish Chandra ^g   Lakhani, Jitendra D ^h   Solanki, Bhagirath B ⁱ   Jalali, Rajinder K ^j   Arora, Sudershan ^j   Roy, Arjun ^j   Saha, Nilanjan ^j   Iyer, Sunil S ^j   Sharma, Pradeep ^j   Anvikar, Anupkumar R ^a  

^a NATIONAL INSTITUTE OF MALARIA RESEARCH   (India)

^b KASTURBA MEDICAL COLLEGE   (India)

^c CALCUTTA SCHOOL OF TROPICAL MEDICINE   (India)

^d KEM HOSPITAL   (India)

^e S P MEDICAL COLLEGE   (India)

^f ANDHRA MEDICAL COLLEGE   (India)

^g BYL NAIR CHARITABLE HOSPITAL   (India)

^h Baroda Medical College   (India)

ⁱ B J MEDICAL COLLEGE   (India)

^j RANBAXY LABORATORIES LTD   (India)

more..

Author keywords

Arterolane maleate and piperaquine phosphate; Chloroquine; Cure rate; Fever clearance time; Fixed dose combination; Parasite clearance time; Pharmacokinetics; Plasmodium vivax; Primary efficacy analysis

Indexed keywords

ANTIMALARIAL AGENT; ARTEROLANE MALEATE PLUS PIPERAQUINE PHOSPHATE; CHLOROQUINE; UNCLASSIFIED DRUG; ARTEROLANE; MALEIC ACID DERIVATIVE; PEROXIDE; PIPERAQUINE; QUINOLINE DERIVATIVE; SINGLE HETEROCYCLIC RINGS; SPIRO COMPOUND;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; DEHYDRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FEVER; GLOMERULONEPHRITIS; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NONHUMAN; PARASITE CLEARANCE; PHASE 3 CLINICAL TRIAL (TOPIC); PLASMODIUM VIVAX MALARIA; QT PROLONGATION; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING; AGED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; MALARIA; MALARIA, VIVAX; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIMALARIALS; CHLOROQUINE; DRUG THERAPY, COMBINATION; FEMALE; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; MALARIA; MALARIA, VIVAX; MALE; MALEATES; MIDDLE AGED; PEROXIDES; QUINOLINES; SPIRO COMPOUNDS; YOUNG ADULT;

EID: 84961352460     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/s12936-016-1084-1     Document Type: Article

References (27)

1. WHO. Guidelines for the treatment of malaria (second edition). Geneva: World Health Organization; 2010. [ http://whqlibdoc.who.int/publications/2010/9789241547925-eng.pdf ].
2. Mishra N, Singh JP, Srivastava B, Arora U, Shah NK, Ghosh SK, et al. Monitoring antimalarial drug resistance in India via sentinel sites: outcomes and risk factors for treatment failure, 2009-2010. Bull World Health Organ. 2012;90:895-904. doi: 10.2471/BLT.12.109124 (Epub 2012 Oct 31).
3. Dua VK, Kar PK, Sharma VP. Chloroquine resistant 22. Plasmodium vivax malaria in India. Trop Med Int Health. 1996;1:816-9.
4. Baird JK. Chloroquine resistance in Plasmodium vivax. Antimicrob Agents Chemother. 2004;48:4075-83.
5. WHO. World Malaria Report. Geneva: World Health Organization. 2013.
6. Battle KE, Karhunen MS, Bhatt S, Gething PW, Howes RE, Golding N. Geographical variation in Plasmodium vivax relapse. Malar J. 2014;13:144.
7. National Institute of Malaria Research, national vector borne disease control programme: guidelines for diagnosis and treatment of malaria in India. Government of India. 2011. [ http://mrcindia.org/TreatmentGuidelineswithAddendum.pdf ].
8. National vector borne disease control programme. Directorate General of Health Services Ministry of Health and Family Welfare: National drug policy on malaria. Government of India. 2013. [ http://www.nvbdcp.gov.in/Doc/National-Drug-Policy-2013.pdf ].
9. US Prescribing Information "Primaquine phosphate tablets". Feb 2013. [ http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1bfbf4ae-81b8-4160-a00d-6322aadd4b59 ].
10. Teka H, Petros B, Yamuah L, Tesfaye G, Elhassan I, Muchohi S, et al. Chloroquine-resistant: Plasmodium vivax malaria in Debre Zeit, Ethiopia. Malar J. 2008;7:220.
11. World Health Organization. Monitoring antimalarial drug resistance. Report of a WHO consultation. Geneva, Switzerland. 3-5 December. 2001. [ http://malaria.who.int/cmc-upload/0/000/015/800/200239.html ].
12. Sinclair D, Zani B, Donegan S, Olliaro P, Garner P. Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database Syst Rev. 2009; 3:CD007483. DOI: 10.1002/14651858.CD007483.pub2.
13. Ratcliff A, Siswantoro H, Kenangalem E, Maristela R, Wuwung RM, Laihad F, et al. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: open label randomized comparison. Lancet. 2007;369:757-65.
14. Davis TM, Hung TY, Sim IK, Karunajeewa HA, Ilett KF. Piperaquine: a resurgent antimalarial drug. Drugs. 2005;65:75-87.
15. Saha N1, Moehrle JJ, Zutshi A, Sharma P, Kaur P, Iyer SS. Safety, tolerability and pharmacokinetic profile of single and multiple oral doses of arterolane (RBx11160) maleate in healthy subjects. J Clin Pharmacol. 2014;54:386-93.
16. Ahmed T, Sharma P, Gautam A, Varshney B, Kothari M, Ganguly S, et al. Safety, tolerability, and single- and multiple-dose pharmacokinetics of piperaquine phosphate in healthy subjects. J Clin Pharmacol. 2008;48:166-75.
17. Guidance for industry, bioanalytical method validation. US Department of Health and Human Services, Food and Drug Administration, Centre for Drug Evaluation and Research (CDER), Centre for Veterinary Medicine (CVM). May 2001.
18. Mendis K, Sina BJ, Marchesini P, Carter R. The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg. 2001;64(1-2 Suppl):97-106.
19. Ratcliff A, Siswantoro H, Kenangalem E, Wuwung M, Brockman A. Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia. Trans R Soc Trop Med Hyg. 2007;101:351-9.
20. Pukrittayakamee S, Chantra A, Simpson JA, Vanijanonta S, Clemens R, Looareesuwan S, et al. Therapeutic responses to different antimalarial drugs in vivax malaria. Antimicrob Agents Chemother. 2000;44:1680-5.
21. deVries PJ, Dien TK: Clinical pharmacology and therapeutic potential of artemisinin and its derivatives in the treatment of malaria. Drugs 1996;52: 818-36.
22. Valecha N, Krudsood S, Tangpukdee N, Mohanty S, Sharma SK, Tyagi PK, et al. Arterolane maleate plus piperaquine phosphate for treatment of uncomplicated Plasmodium falciparum malaria: a comparative, multicenter, randomized clinical trial. Clin Infect Dis. 2012;55:663-71.
23. Data on file Ranbaxy. A Phase 3, Double blind, Randomised study of arterolane maleate + Piperaquine phosphate Versus artemether-lumefantrine for falciparum malaria in Asia and Africa.
24. Eibach D, Ceron N, Krishnalall K, Carter K, Bonnot G, Bienvenu AL, et al. Therapeutic efficacy of artemether-lumefantrine for Plasmodium vivax infections in a prospective study in Guyana. Malar J. 2012;11:347.
25. Mytton OT, Ashley EA, Peto L, Price RN, La Y, Hae R, et al. Electrocardiographic safety evaluation of dihydroartemisinin-piperaquine in the treatment of uncomplicated falciparum malaria. Am J Trop Med Hyg. 2007;77:447-50.
26. Yap YG, Camm AJ. Drug induced QT prolongation and Torsades de Pointes. Heart. 2003;89:1363-72.
27. Na-Bangchang K, Limpaibul L, Thanavibul A, Tan-Ariya P, Karbwang J. The pharmacokinetics of chloroquine in healthy Thai subjects and patients with Plasmodium vivax malaria. Br J Clin Pharmacol. 1994;38:278-81.